Matchpoint Therapeutics Nets $150M in Series B
2026-10-07
Tweet
WATERTOWN, MA, Matchpoint Therapeutics announced the successful closing of a $150 million Series B financing co-led by Nextech Invest and Norwest.
Matchpoint Therapeutics, a biotechnology company pioneering the discovery of precision covalent medicines, today announced the successful closing of a $150 million Series B financing.
The financing was co-led by Nextech Invest and Norwest, with participation from new investors Invus, BB Biotech, T1D Fund, and BOLD Longevity Growth.
The financing was co-led by Nextech Invest and Norwest, with participation from new investors Invus, BB Biotech, T1D Fund, and BOLD Longevity Growth.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors
